Download MendeleyDiscovery of BI-2493, a Pan-KRAS Inhibitor Showing In Vivo Efficacy.
Broker, J., Waterson, A.G., Hodges, T.R., Abbott, J.R., Arnold, A., Bottcher, J., Braun, N., Cui, J., Fuchs, J.E., Gerstberger, T., Gogg, S., Hanner, S., Herdeis, L., Howell, L.W., Mantoulidis, A., Mayer, M., Phan, J., Rocchetti, F., Sankar, K., Sarkar, D., Schaaf, O., Sensintaffar, J.L., Sun, Q., Wunberg, T., Fesik, S.W.(2025) J Med Chem
- PubMed: 40709733
- DOI: https://doi.org/10.1021/acs.jmedchem.5c00576
- Primary Citation of Related Structures:
9IAP, 9IAW, 9IAY, 9IB4, 9IB5 - PubMed Abstract:
KRAS is one of the most highly validated cancer targets. Here we describe the design and synthesis of two reversible pan-KRAS inhibitors, BI-2865 and BI-2493. From our KRAS G12C inhibitor program, we identified BI-2865, a potent noncovalent KRAS inhibitor that showed cellular activity against a broad spectrum of KRAS alleles and selectivity against HRAS and NRAS. Spirocyclization led to the discovery of BI-2493, a highly rigid analogue exhibiting better potency, metabolic stability, and permeability. BI-2493 shows in vivo efficacy in various KRAS mutant and KRAS wild-type amplified xenograft models and represents a promising starting point for further optimization.
Organizational Affiliation:
Boehringer Ingelheim RCV GmbH & Co., KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria.
